Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes

Sei-Ichiro Motegi; Mai Ishikawa; Akiko Sekiguchi; Osamu Ishikawa

doi:10.1159/000503271

Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes

Case Rep Dermatol. 2019 Oct 2;11(3):273-277. doi: 10.1159/000503271. eCollection 2019 Sep-Dec.

Authors

Sei-Ichiro Motegi¹, Mai Ishikawa¹, Akiko Sekiguchi¹, Osamu Ishikawa¹

Affiliation

¹ Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.

Abstract

We herein present the first case of nanoparticle albumin-bound paclitaxel (nab-paclitaxel)- and/or gemcitabine-induced scleroderma accompanied by acanthosis nigricans-like skin changes in a 54-year-old Japanese male. He was diagnosed with pancreatic cancer and received 17 courses of nab-paclitaxel and gemcitabine chemotherapy. Edema and skin sclerosis in his legs appeared after the first and third course, respectively. Histological examination of the hyperkeratotic lesion of the ankle revealed hyperkeratosis, acanthosis, papillomatosis, increased number of melanocytes in the basal layer, and dermal fibrosis. Awareness of the clinical characteristics of nab-paclitaxel- and/or gemcitabine-induced scleroderma accompanied by acanthosis nigricans-like skin changes is important for dermatologists to establish an accurate diagnosis.

Keywords: Acanthosis nigricans; Gemcitabine; Nanoparticle albumin-bound paclitaxel; Scleroderma.

Publication types

Case Reports